Biotech Stock Live Chat: 2012 Preview
BOSTON (TheStreet) -- Welcome to December's Biotech Stock Mailbag Live Chat. The floor is yours.
I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.
Is there any hope for BioSante Pharma's (BPAX) future after the Libigel blow up? What about Antares Pharma (AIS) -- is it also mortally wounded?
Vertex Pharmaceuticals (VRTX) announced a CEO swap this morning Surprised? Does this signal more changes in store for the company as it transitions from a focus on hepatitis C to cystic fibrosis? We can talk about YM BioSciences (YMI) and what lies ahead after this week's presentation of strong data on the myelofibrosis drug CYT387. Can YM Bio's market cap catch up to that of rival Incyte (INCY)? Were you confused by this week's Alexza Pharmaceuticals (ALXA) FDA panel? Me too, but let's hash out the future for Adasuve. The year is almost over, so it's time to look ahead to key biotech events in 2012, including results from late-stage cancer immunotherapy trials involving Oncothyreon (ONTY) and Vical (VICL). And let's not forget that obesity drug stocks Arena Pharma (ARNA) and Vivus (VVUS) should be volatile again in 2012. Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live. --Written by Adam Feuerstein in Boston.>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
